Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    2(67%)

    Phase Distribution

    Phase 2
    1
    33%
    Phase 3
    1
    33%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    2

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(2)
    Other(1)

    Detailed Status

    unknown1
    Recruiting1
    Active, not recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    2
    Success Rate
    N/A
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    unknown133%
    recruiting133%
    active_not_recruiting133%

    Recent Activity

    2 active trials
    Showing 3 of 3
    active_not_recruitingphase_2

    Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

    NCT03743662
    recruiting

    The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

    NCT06283927
    unknownphase_3

    TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma

    NCT01833286

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT03743662Phase 2

    Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

    Active Not Recruiting
    NCT06283927

    The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

    Recruiting
    NCT01833286Phase 3

    TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma

    Unknown

    All 3 trials loaded

    Drug Details

    Intervention Type
    Procedure
    Total Trials
    3